›› 2017, Vol. 35 ›› Issue (3): 223-.doi: 10.3969/j.issn.1000-3606.2017.03.017

Previous Articles     Next Articles

Systematic review of the effectiveness of intratracheal injection of pulmonary surfactant in the treatment of neonatal respiratory distress syndrome 

 XU Fen1, LUO Jun1, LI Hongping1, HUANG Yan1, LIN HungChih 2   

  1. 1.Department of Neonatalogy, ShenzhenBao'an District Maternal and Child Health Care Hospital, Shenzhen, Guangdong 518133, China; 2. Department of Pediatrics and School of Chinese Medicine, China Medical University Hospital, China Medical University, Taichung 404, Taiwan, China
  • Received:2017-03-15 Online:2017-03-15 Published:2017-03-15

Abstract: Objective To evaluate the effectiveness of intratracheal injection of pulmonary surfactant (LISA) combined with continuous positive airway pressure (CPAP) on the treatment of neonatal respiratory distress syndrome (RDS). Methods  The databases of PubMed, EMBASE, Cochrane, China National Knowledge Infrastructure (CNKI), Wanfang Database, Weipu Database and China Biology Medicine disc (CBM) were searched, and all of the randomized controlled trial of LISA combined with CPAP for treatment of RDS were included. RevMan 5.2 was used to perform meta-analysis. The differences of mortality, bronchopulmonary dysplasia (BPD), retinopathy of prematurity (ROP), intraventricular hemorrhage (IVH), periventricular leukomalacia (PVL), and other complications between LISA group and control group were compared in <34 weeks gestational age preterm infants with RDS. Results Five randomized controlled trials were included with 759 infants in total. Compared with control group, the rate of mechanical ventilation (RR: 0.32,95% CI: 0.13-0.82) and the incidence of BPD (RR: 0.61,95% CI: 0.42-0.88) were significantly decreased in LISA group. There were no differences in mortality and the incidences of ROP, IVH, and PVL between two groups (P>0.05). Conclusion The mechanical ventilation and the incidence of BPD is significantly reduced in the treatment of neonatal respiratory distress syndrome by LISA, but it has no effect on the incidences of other complications and mortality.